Glycopyrrolate 1 mg Tablet, 90-count
Other active recalls for Glycopyrrolate (different manufacturers) — 4 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Anticholinergic class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
Glycopyrrolate is used in combination with other medications to treat ulcers in adults and children 12 years of age and older. Glycopyrrolate (Cuvposa) is used to reduce saliva and drooling in children between 3 and16 years of age that have certain medical conditions that cause drooling. Glycopyrrolate is in a class of medications called anticholinergics. It decreases stomach acid and saliva production by blocking the activity of a certain natural substance in the body.
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Glycopyrrolate — tap one for details:
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Where does this data come from?
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII L11K75P92J
A mineral salt made from calcium and phosphate. It acts as a filler and binder in tablets to add bulk and help hold the medicine together in solid form.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.099 | $8.89 / 90 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.2126 | $19.13 / 90 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.1993 | $17.94 / 90 tablets |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Glycopyrrolate 1 mg 00904-6709-61 | Major | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 13107-0014-01 | Aurolife | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mgthis 16571-0743-09 | Rising | 90 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 23155-0606-01 | Heritage | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 49884-0065-01 | Par | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 50268-0363-15 | AvPAK | 50 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 60687-0458-01 | American | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 62135-0734-60 | Chartwell | 60 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 69076-0475-01 | Quinn | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 69315-0139-01 | Leading | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 70752-0108-10 | QUAGEN | 100 tablets | $0.099 | AA | Availability likely | — |
| Glycopyrrolate 1 mg 00615-8617-39 | NCS | 30 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 15955-0305-01 | Alembic | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 55111-0648-01 | Dr. | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 63629-2206-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 63629-7207-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 63629-9287-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 70518-4597-00 | REMEDYREPACK | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 71335-2075-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 71335-3090-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 71335-9652-01 | Bryant | 30 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 71921-0110-01 | Florida | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 72162-1477-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 72162-2597-01 | Bryant | 100 tablets | — | AA | FDA listed | — |
| Glycopyrrolate 1 mg 55111-0649-01 | Dr. | 100 tablets | — | AA | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
🗺️ Medicaid utilization & spend
💊 Medicaid utilization by pack size
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 16571-0743-03 | 30 TABLET in 1 CONTAINER (16571-743-03) | — | — | 2020-10-06 | Active |
| 16571-0743-09 You're viewing this | 90 TABLET in 1 CONTAINER (16571-743-09) | $0.0988 / ea | $8.89 | 2020-10-06 | Active |
You're viewing the largest of 2 pack sizes for this product.
In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 16571-0743-09?
What is the difference between NDC 16571-0743-09 and NDC 16571-0743-03?
What NDC number is used to bill for this package of Glycopyrrolate 1 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
📄 Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS & USAGE Glycopyrrolate are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Limitations of Use Glycopyrrolate are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. Glycopyrrolate are anticholinergics indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.
(1) Limitations of Use: Not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. (1)
⏱️ Dosage and Administration ▾
2 DOSAGE & ADMINISTRATION Important Dosing Information (2.1) • Glycopyrrolate is not recommended for patients initiating treatment or receiving maintenance treatment with glycopyrrolate or another 1 mg dosage strength of oral glycopyrrolate tablets. Recommended Dosage (2.2) • The recommended initial dosage of glycopyrrolate is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms.
For maintenance, a dosage of 1 mg twice a day is frequently adequate. • The recommended dosage of glycopyrrolate for adults is 2 mg two or three times daily at equally spaced intervals. • The maximum recommended daily dosage is 8 mg. • Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate or another 1 mg oral tablet of glycopyrrolate.
2.1Important Dosing Information • Glycopyrrolate is not recommended for patients in whom a lower dosage strength of oral glycopyrrolate (e.g., glycopyrrolate or another 1 mg tablet strength) is appropriate for initial or maintenance treatment because the dosage strength of glycopyrrolate may exceed the recommended initial and maintenance dosage of oral glycopyrrolate tablets.
2.2Recommended Dosage • The recommended initial dosage of glycopyrrolate for adults is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate. • The recommended dosage of glycopyrrolate for adults is 2 mg two or three times daily at equally spaced intervals. • The maximum recommended daily dosage of glycopyrrolate is 8 mg. • Use the lowest effective dosage of glycopyrrolate to control symptoms.
If patients can be titrated to a lower dose, switch from glycopyrrolate or another 1 mg oral tablet of glycopyrrolate.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS & STRENGTHS Tablets: • 1 mg, white, round, flat-faced, beveled-edge tablet, debossed “CS” and “007” on one side and functionally scored on the other side. • 2 mg, white, round, flat-faced, beveled-edge tablet, debossed “CS” score “008” on one side and plain on the other side. • Tablets: 1 mg (functionally scored) and 2 mg (3)
⛔ Contraindications ▾
4 CONTRAINDICATIONS Glycopyrrolate are contraindicated in: • Patients at risk for anticholinergic toxicity due to an underlying medical condition, including: o Glaucoma [ see Warnings and Precautions (5.1) ] o Obstructive uropathies, including prostatic hypertrophy o Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [ see Warnings and Precautions (5.2) ] o Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [ see Warnings and Precautions (5.3) ] o Bleeding gastrointestinal ulcer o Active inflammatory or infectious colitis which can lead to toxic megacolon o History of or current toxic megacolon o Myasthenia gravis • Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate [ see Adverse Reactions (6) and Description (11) ]. • Patients at risk for anticholinergic toxicity due to various underlying medical conditions.
( 4 , 5.1 , 5.2 , 5.3 ) • Hypersensitivity to glycopyrrolate or the inactive ingredients. (4)
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Precipitation of Acute Glaucoma : May increase intraocular pressure; if symptoms occur, discontinue use and promptly seek medical care. ( 4 , 5.1 ) • Partial or Complete Mechanical Intestinal Obstruction : Diarrhea may be an early symptom, especially in patients with ileostomy or colostomy. If the obstruction is suspected, discontinue use and evaluate the patient for obstruction.
( 4 , 5.2 ) • GI Adverse Reactions Due to Decreased GI Motility : Delayed gastric emptying, constipation, and intestinal pseudo-obstruction may occur and precipitate or aggravate paralytic ileus and toxic megacolon; not recommended for use with anticholinergics or other medications that decrease GI peristalsis. ( 4 , 5.3 , 7.1 ) • Cognitive and Visual Adverse Reactions : May impair mental and/or physical function. Inform patients not to operate motor vehicles or perform other hazardous tasks until reasonably certain they are not adversely affected; discontinue use if signs or symptoms develop.
( 5.4 , 7.1 ) • Heat Prostration at High Environmental Temperatures : Heat prostration resulting in fever and heatstroke can occur, especially in geriatric patients. Avoid exposure to hot or very warm environmental temperatures. ( 5.5 , 5.7 ) • Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc.
( 5.6 , 7.1 ) • Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients : Complications include urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures. Not recommended in geriatric patients and may be contraindicated in some patients with underlying medical conditions. ( 4 , 5.7 , 8.5 )
5.1Precipitation of Acute Glaucoma Glycopyrrolate may cause increased intraocular pressure in patients with glaucoma and reduce the effects of antiglaucoma agents. Instruct patients to discontinue glycopyrrolate and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [ see Contraindications (4) ].
5.2Partial or Complete Mechanical Intestinal Obstruction Glycopyrrolate may worsen intestinal mechanical obstruction, and diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. If partial or complete intestinal obstruction is suspected, discontinue the use of glycopyrrolate and evaluate for potential intestinal obstruction [ see Contraindications (4) ].
5.3Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility Glycopyrrolate reduces gastrointestinal motility and may result in delayed gastric emptying, constipation, and intestinal pseudo-obstruction and may precipitate or aggravate paralytic ileus and toxic megacolon [ see Contraindications (4) ]. The risk of gastrointestinal adverse reactions is further increased with the use of other anticholinergics and other medications that decrease gastrointestinal peristalsis. Monitor patients for symptoms of decreased gastrointestinal motility.
Concomitant use of glycopyrrolate and other anticholinergics or other medications that decrease GI peristalsis is not recommended [ see Drug Interactions (7.2) ].
5.4Cognitive and Visual Adverse Reactions Glycopyrrolate may produce drowsiness and blurred vision and impair the mental and/or physical abilities required for the performance of hazardous tasks such as driving a motor vehicle, operating machinery, or performing other hazardous work [ see Adverse Reactions (6) ]. Concomitant use of other drugs that have anticholinergic properties may increase these effects [ see Drug Interactions (7.1) ]. Inform patients not to operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate does not affect them adversely.
Discontinue gly…
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are discussed elsewhere in the labeling: • Precipitation of Acute Glaucoma [ see Warnings and Precautions (5.1) ] • Partial or Complete Mechanical Intestinal Obstruction [ see Warnings and Precautions (5.2) ] • Gastrointestinal Adverse Reactions due to Decreased Gastrointestinal Motility [ see Warnings and Precautions (5.3) ] • Cognitive and Visual Adverse Reactions [ see Warnings and Precautions (5.4) ] • Heat Prostration at High Environmental Temperatures [ see Warnings and Precautions (5.5) ] • Other Conditions Exacerbated by Anticholinergic Adverse Reactions [ see Warnings and Precautions (5.6) ] • Increased Risk of Anticholinergic Adverse Reactions in Geriatric Patients [ see Warnings and Precautions (5.7) ] The following adverse reactions associated with the use of glycopyrrolate, or other anticholinergic drugs, were identified in clinical studies or postmarketing reports.
Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiac Disorders: chest, pain, hypertension, tachycardia Endocrine Disorders: decreased sweating Eye Disorders: blurred vision, cycloplegia, dilatation of the pupil, increased ocular tension Gastrointestinal Disorders: bloated feeling, constipation, dry mouth, dysgeusia, nausea, vomiting Immune System Disorders: anaphylaxis [ see Contraindications (4) ] Nervous System Disorders: agitation, dizziness, drowsiness, headache, insomnia, mental confusion, nervousness, weakness Respiratory Disorders: respiratory depression, throat irritation Renal and Urinary Disorders: urinary hesitancy, urinary retention Reproductive System and Breast Disorders: impotence, suppression of lactation Vascular Disorders: flushing Adverse reactions include blurred vision, drowsiness, decreased sweating, flushing, vomiting, constipation, dry mouth, tachycardia, and urinary retention.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS • Other Anticholinergic Drugs : Concomitant use is not recommended. ( 5.3 , 5.4 , 5.6 , 7.1 ) • Drugs with Altered Absorption due to Decreased GI Motility : Concomitant use is not recommended. ( 7.2 ) • GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. ( 7.3 )
7.1Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. Co-administration of antipsychotics with glycopyrrolate may lead to worsening of tardive dyskinesia. Glycopyrrolate are not recommended in patients taking other anticholinergic drugs [ see Warnings and Precautions (5.3 , 5.4 , 5.6 ) ].
7.2Drugs with Altered Absorption due to Decreased Gastrointestinal Motility and Increased Transit Time Decreased gastrointestinal motility by glycopyrrolate may impact absorption of other drugs leading to increased or decreased drug exposure. Glycopyrrolate are not recommended in patients taking other drugs that are affected by altered gastrointestinal motility [ see Warnings and Precautions (5.3) ] .
7.3Gastrointestinal Toxicity with Solid Oral Dosage Forms of Potassium Chloride Oral glycopyrrolate may worsen gastrointestinal mucosal injury reported with solid oral dosage forms of potassium chloride due to decreased gastric motility and increased transit time, leading to prolonged contact with the gastrointestinal mucosa. Glycopyrrolate are not recommended in patients taking solid oral dosage forms of potassium chloride.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS • Renal Impairment : Monitor patients with renal impairment; if anticholinergic adverse reactions occur, discontinue use. ( 8.6 )
8.1Pregnancy Risk Summary Over decades of use, there is an absence of published data on orally administered glycopyrrolate in pregnant women, including an absence of any reports of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, at non-maternally toxic doses of oral glycopyrrolate, there were no adverse developmental effects in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed ( see Data ).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data At non-maternally toxic doses of oral glycopyrrolate, there were no effects on embryo-fetal development or toxicity in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed. In a published reproductive and developmental study, male and female rats were administered glycopyrrolate in the diet at 0 mg/kg/day, 32.5 mg/kg/day, 63 mg/kg/day, and 130 mg/kg/day for 3 weeks to 5 weeks and through up to three consecutive litters.
There was no indication of abnormalities in the pups of treated dams. There was a decreased rate of conception and in survival rate at weaning for all treated animals in a dose-related manner. Diminished rates of conception may be due to diminished seminal secretion [ see Nonclinical Toxicology (13.1) ].
8.2Lactation Risk Summary There are no data on the presence of glycopyrrolate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. As with other anticholinergic drugs, glycopyrrolate may cause suppression of lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for glycopyrrolate and any potential adverse effects on the breastfed infant from glycopyrrolate.
8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.
8.5Geriatric Use Geriatric patients 65 years of age and older may be more sensitive to the anticholinergic adverse reactions of glycopyrrolate leading to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures; therefore, glycopyrrolate are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [ see Contraindications (4) and Warnings and Precautions (5) ].
8.6Renal Impairment Glycopyrrolate is substantially excreted by the kidney [ see Clinical Pharmacology (12.3) ]. Monitor patients with renal impairment for anticholinergic adverse reactions [ see Adverse Reactions (6) ]. If anticholinergic adverse reactions occur, discontinue glycopyrrolate.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary Over decades of use, there is an absence of published data on orally administered glycopyrrolate in pregnant women, including an absence of any reports of a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal studies, at non-maternally toxic doses of oral glycopyrrolate, there were no adverse developmental effects in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed ( see Data ).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data At non-maternally toxic doses of oral glycopyrrolate, there were no effects on embryo-fetal development or toxicity in rats or rabbits. A pre- and post-natal development study of oral glycopyrrolate in rats showed a decrease in pup mean bodyweight that recovered post nursing, with no other developmental effects observed. In a published reproductive and developmental study, male and female rats were administered glycopyrrolate in the diet at 0 mg/kg/day, 32.5 mg/kg/day, 63 mg/kg/day, and 130 mg/kg/day for 3 weeks to 5 weeks and through up to three consecutive litters.
There was no indication of abnormalities in the pups of treated dams. There was a decreased rate of conception and in survival rate at weaning for all treated animals in a dose-related manner. Diminished rates of conception may be due to diminished seminal secretion [ see Nonclinical Toxicology (13.1) ].
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and effectiveness in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Geriatric patients 65 years of age and older may be more sensitive to the anticholinergic adverse reactions of glycopyrrolate leading to complications of urinary retention, bowel obstruction, heat prostration, arrhythmias, delirium, and falls or fractures; therefore, glycopyrrolate are not recommended in geriatric patients and may be contraindicated in some geriatric patients with underlying medical conditions [ see Contraindications (4) and Warnings and Precautions (5) ].
🆘 Overdosage ▾
10 OVERDOSAGE Signs and symptoms of glycopyrrolate overdosage are related to excessive anti-muscarinic anticholinergic activity and are generally peripheral (e.g., flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation, and light sensitivity due to mydriasis), but central nervous system toxicity (agitation, seizures, hyperthermia) may also occur. If over-exposure occurs, call the Poison Control Center at 1-800-222-1222 for current information on the management of glycopyrrolate poisoning and overdosage.
Management of glycopyrrolate overdosage is based upon presenting signs and symptoms, including close observation for severe or life-threatening complications which may require respiratory and cardiovascular monitoring and support. Consider administration of activated charcoal and/or use of a reversible anticholinesterase as appropriate or recommended by Poison Control.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.
12.2Pharmacodynamics No formal pharmacodynamic studies have been conducted with glycopyrrolate.
12.3Pharmacokinetics Patients with Renal Impairment In the published literature, glycopyrrolate 4 mcg/kg was administered intravenously (glycopyrrolate are not recommended for intravenous use) in uremic patients undergoing renal transplantation surgery. The mean AUC (10.6 mcg·h/L) and 24-hour urinary excretion (7%) for glycopyrrolate were significantly different from normal healthy adult subjects undergoing general surgery (3.7 mcg·h/L, and 65%, respectively) [ see Use in Specific Populations (8.6) ] .
🧬 Mechanism of Action ▾
12.1Mechanism of Action Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Glycopyrrolate Tablets USP, 1 mg are white, round, flat-faced, beveled-edge tablet, debossed “CS” and “007” on one side and functionally scored on the other side. Available as • Bottles of 30 NDC 16571-743-03 • Bottles of 90 NDC 16571-743-09 Glycopyrrolate Tablets USP, 2 mg are white, round, flat-faced, beveled-edge tablet, debossed “CS” score “008” on one side and plain on the other side. Available as • Bottles of 30 NDC 16571-744-03 • Bottles of 90 NDC 16571-744-09 Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Keep out of reach of children. Dispense in tight container.
📋 Description ▾
11 DESCRIPTION Glycopyrrolate Tablets, USP contain synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentyl hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. The molecular formula for glycopyrrolate is C 19 H 28 BrNO 3 , the molecular weight is 398.3 g/mol, and the structural formula is: Each glycopyrrolate tablet contains glycopyrrolate, USP 1 mg, as the active ingredient.
Each glycopyrrolate tablet contains glycopyrrolate, USP 2 mg, as the active ingredient. The inactive ingredients are dibasic calcium phosphate, lactose monohydrate, magnesium stearate, povidone, and sodium starch glycolate. glycopyrrolate-struct.jpg
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Precipitation of Acute Glaucoma Advise patients to discontinue glycopyrrolate and promptly seek medical care if they experience symptoms of acute angle-closure glaucoma (pain and reddening of the eyes accompanied by dilated pupils) [ see Warnings and Precautions (5.1) ]. Partial or Complete Mechanical Intestinal Obstruction Advise patients to contact their healthcare provider if diarrhea occurs, especially in patients with ileostomy or colostomy [ see Warnings and Precautions (5.2) ].
Gastrointestinal Adverse Reactions Due to Decreased Gastrointestinal Motility Inform patients that glycopyrrolate may cause adverse reactions related to decreased gastrointestinal motility and report to their healthcare provider if they experience symptoms such as vomiting, early satiety, abdominal distention, and constipation [ see Warnings and Precautions (5.3) ]. Cognitive and Visual Adverse Reactions Inform patients that glycopyrrolate may cause cognitive or visual impairment and not operate motor vehicles or other dangerous machinery or perform other hazardous tasks until they are reasonably certain that glycopyrrolate do not affect them adversely.
Advise patients to discontinue glycopyrrolate immediately and contact their healthcare provider if symptoms develop (e.g., drowsiness or blurred vision) [ see Warnings and Precautions (5.4) ]. Heat Prostration at High Environmental Temperatures Inform patients that glycopyrrolate can reduce sweating, leading to the possibility of heat exhaustion or heat stroke. Advise patients to avoid exposure to hot or very warm environmental temperatures [ see Warnings and Precautions (5.5) ].
Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Made in India Neutral code: 4323147/TS/DRUGS/2025 Revised: 08/2025 PIA74409-04